文献速递核素与放射性配体治疗放射性药物与辐射防护

格隆溴铵抑制唾液腺毒蕈碱受体未降低PSMA配体或放射性碘摄取

Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine.
PubMed 文献 · EJNMMI Res · 2021-03-12

本研究探讨抗毒蕈碱药物格隆溴铵(GPB)能否减少唾液腺对PSMA配体或放射性碘的摄取。4例甲状腺癌随访患者接受123I平面显像,比较肌内注射0.4 mg GPB前后摄取。结果显示GPB未显著降低PSMA摄取,且多数患者123I摄取反而增加,提示该策略无效。

要点

  • GPB未显著降低腮腺或颌下腺对68Ga-PSMA-11的摄取。
  • GPB后4例中3例唾液腺123I摄取增加,而非减少。
  • 以GPB减少唾液腺辐射剂量的策略可被否定。

核心结论

  • 格隆溴铵抑制唾液分泌未显著降低唾液腺对PSMA配体或放射性碘的摄取,不能作为减少核素治疗唾液腺毒性的策略。

研究设计与样本

  • 4例甲状腺癌随访患者接受123I平面显像,比较肌内注射0.4 mg GPB前后唾液腺摄取。

主要发现

  • 腮腺平均SULmean对照组5.57、干预组5.72,p=0.50;颌下腺平均SULmean对照组6.25、干预组5.89,p=0.12。
  • 4例中3例GPB后唾液腺123I摄取增加,平均每像素计数对照组8.60、干预组11.46。

临床怎么用

  • 不应使用格隆溴铵来预防或减轻PSMA靶向治疗或131I治疗相关的唾液腺辐射损伤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Salivary glands are highly perfused and express the prostate-specific membrane antigen (PSMA) receptor as well as the sodium-iodide symporter. As a consequence, treatment with 177Lu/225Ac-PSMA for prostate cancer or 131I for thyroid cancer leads to a high radiation dose in the salivary glands, and patients can be confronted with persistent xerostomia and reduced quality of life. Salivation can be inhibited using an antimuscarinic pharmaceutical, such as glycopyrronium bromide (GPB), which may also reduce perfusion. The primary objective of this work was to determine if inhibition with GPB could provide a considerable (> 30%) reduction in the accumulation of administered 123I or 68Ga-PSMA-11 in salivary glands. METHODS: Ten patients who already received a whole-body 68Ga-PSMA-11 PET/CT scan for (re)staging of prostate cancer underwent a repeat PET/CT scan with tracer administration at 90 min after intravenous injection of 0.2 mg GPB. Four patients in follow-up after thyroid cancer, who had been treated with one round of ablative 131I therapy with curative intent and had no signs of recurrence, received 123I planar scintigraphy at 4 h after tracer administration without GPB and a repeated scan at least one week later, with tracer administration at 30 min after intramuscular injection of 0.4 mg GPB. Tracer uptake in the salivary glands was quantified on PET and scintigraphy, respectively, and values with and without GPB were compared. RESULTS: No significant difference in PSMA uptake in the salivary glands was seen without or with GPB (Mean SULmean parotid glands control 5.57, intervention 5.72, p = 0.50. Mean SULmean submandibular glands control 6.25, intervention 5.89, p = 0.12). Three out of 4 patients showed increased 123I uptake in the salivary glands after GPB (Mean counts per pixel control 8.60, intervention 11.46). CONCLUSION: Muscarinic inhibition of salivation with GPB did not significantly reduce the uptake of PSMA-ligands or radioiodine in salivary glands, and can be dismissed as a potential strategy to reduce toxicity from radionuclide therapies.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Mohan V, Bruin NM, Tesselaar MET, et al. Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine. EJNMMI Res. 2021. PMID: 33710423. doi:10.1186/s13550-021-00770-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。